Sarah F. Giardina

Sarah F. Giardina

Auto-generated profile, based on publicly available information

Sarah F. Giardina

Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MSMichal Sheffer
Michal Sheffer
Manny BacolodManny Bacolod
Manny Bacolod
OZOr Zuk
Or Zuk
SGSarah F. Giardina
Sarah F. Giardina
HPHanna Pincas
Hanna Pincas
EDEytan Domany
Eytan Domany
During disease progression the cells that comprise solid malignancies undergo significant changes in gene copy number and chromosome structure. Colorectal cancer provides an excellent model to study this process. To indentify and characterize chromosomal abnormalities in colorectal cancer, we performed a statistical analysis of 299 expression and 130 SNP arrays profiled at different stages of the disease, including normal tissue, adenoma, stages 1–4 adenocarcinoma, and metastasis. We identified broad (> 1/2 chromosomal arm) and focal (< 1/2 chromosomal arm) events. Broad amplifications were noted on chromosomes 7, 8q, 13q, 20, and X and broad deletions on chromosomes 4, 8p, 14q, 15q, 17p, 18, 20p, and 22q. Focal events (gains or losses) were identified in regions containing known cancer pathway genes, such as VEGFA , MYC , MET , FGF6 , FGF23 , LYN , MMP9 , MYBL2 , AURKA , UBE2C , and PTEN . Other focal events encompassed potential new candidate tumor suppressors (losses) and oncogenes (gains), including CCDC68 , CSMD1 , POLR1D , and PMEPA1 . From the expression data, we identified genes whose expression levels reflected their copy number changes and used this relationship to impute copy number changes to samples without accompanying SNP data. This analysis provided the statistical power to show that deletions of 8p, 4p, and 15q are associated with survival and disease progression, and that samples with simultaneous deletions in 18q, 8p, 4p, and 15q have a particularly poor prognosis. Annotation analysis reveals that the oxidative phosphorylation pathway shows a strong tendency for decreased expression in the samples characterized by poor prognosis.

1 October 1998 in Neuropharmacology
Verified
Journal Article
Closed access
NCNam S Cheung
Nam S Cheung
CPCatherine J Pascoe
Catherine J Pascoe
SGSarah F Giardina
Sarah F Giardina
CJChristopher A John
Christopher A John
PBPhilip M Beart
Philip M Beart

1 January 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
FGFarida Goubaeva
Farida Goubaeva
MMMaya Mikami
Maya Mikami
SGSarah Giardina
Sarah Giardina
BDBo Ding
Bo Ding
JAJunichi Abe
Junichi Abe
JYJay Yang
Jay Yang

30 September 2008 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YCYu-Wei Cheng
Yu-Wei Cheng
HPHanna Pincas
Hanna Pincas
Manny BacolodManny Bacolod
Manny Bacolod
GSGunter Schemmann
Gunter Schemmann
SGSarah F. Giardina
Sarah F. Giardina
FBFrancis Barany
Francis Barany
Purpose: Aberrant promoter methylation and genomic instability occur frequently during colorectal cancer development. CpG island methylator phenotype (CIMP) has been shown to associate with microsatellite instability, and BRAF mutation and is often found in the right-side colon. Nevertheless, the relative importance of CIMP and chromosomal instability (CIN) for tumorigenesis has yet to be thoroughly investigated in sporadic colorectal cancers. Experimental Design: We determined CIMP in 161 primary colorectal cancers and 66 matched normal mucosae using a quantitative bisulfite/PCR/ligase detection reaction (LDR)/Universal Array assay. The validity of CIMP was confirmed in a subset of 60 primary tumors using MethyLight assay and five independent markers. In parallel, CIN was analyzed in the same study cohort using Affymetrix 50K Human Mapping arrays. Results: The identified CIMP-positive cancers correlate with microsatellite instability (P = 0.075) and the BRAF mutation V600E (P = 0.00005). The array-based high-resolution analysis of chromosomal aberrations indicated that the degree of aneuploidy is spread over a wide spectrum among analyzed colorectal cancers. Whether CIN was defined by copy number variations in selected microsatellite loci (criterion 1) or considered as a continuous variable (criterion 2), CIMP-positive samples showed a strong correlation with low-degree chromosomal aberrations (P = 0.075 and P = 0.012, respectively). Similar correlations were observed when CIMP was determined by MethyLight assay (P = 0.001 and P = 0.013, respectively). Conclusion: CIMP-positive tumors generally possess lower chromosomal aberrations, which may only be revealed using a genome-wide approach. The significant difference in the degree of chromosomal aberrations between CIMP-positive and the remainder of samples suggests that epigenetic (CIMP) and genetic (CIN) abnormalities may arise from independent molecular mechanisms of tumor progression.

1 October 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SGSarah F Giardina
Sarah F Giardina
MMMaya Mikami
Maya Mikami
FGFarida Goubaeva
Farida Goubaeva
JYJay Yang
Jay Yang

15 October 2006 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YWYu Wen
Yu Wen
SGSarah F. Giardina
Sarah F. Giardina
DHDavid Hamming
David Hamming
JGJennifer Greenman
Jennifer Greenman
EZEmmanuel Zachariah
Emmanuel Zachariah
DNDaniel Notterman
Daniel Notterman
Purpose: The growth-related oncogene α (GROα) is a secreted interleukin-like molecule that interacts with the CXCR2 G-protein–coupled receptor. We found that the mRNA and protein products of GROα are more highly expressed in neoplastic than normal colon epithelium, and we studied potential mechanisms by which GROα may contribute to tumor initiation or growth. Experimental Design: Cell lines that constitutively overexpress GROα were tested for growth rate, focus formation, and tumor formation in a xenograft model. GROα expression was determined by Affymetrix GeneChip (241 microdissected colon samples), real-time PCR (n = 32), and immunohistochemistry. Primary colon cancer samples were also employed to determine copy number changes and loss of heterozygosity related to the GROα and fibulin-1 genes. Results: In cell cultures, GROα transfection transformed NIH 3T3 cells, whereas inhibition of GROα by inhibitory RNA was associated with apoptosis, decreased growth rate, and marked up-regulation of the matrix protein fibulin-1. Forced expression of GROα was associated with decreased expression of fibulin-1. Expression of GROα mRNA was higher in primary adenocarcinomas (n = 132), adenomas (n = 32), and metastases (n = 52) than in normal colon epithelium (P < 0.001). These results were confirmed by real-time PCR and by immunohistochemistry. Samples of primary and metastatic colon cancer showed underexpression of fibulin-1 when compared with normal samples. There were no consistent changes in gene copy number of GROα or fibulin-1, implying a transcriptional basis for these findings. Conclusion: Elevated expression of GROα is frequent in adenocarcinoma of the colon and is associated with down-regulation of the matrix protein fibulin-1 in experimental models and in clinical samples. GROα overexpression abrogates contact inhibition in cell culture models, whereas inhibition of GROα expression is associated with apoptosis. Importantly, coexpression of fibulin-1 with GROα abrogates key aspects of the transformed phenotype, including tumor formation in a murine xenograft model. Targeting GRO proteins may provide new opportunities for treatment of colon cancer.